Click Therapeutics
Click Therapeutics develops and commercializes software as prescription medical treatments, focusing on cognitive and neurobehavioral mechanisms to address unmet medical needs. Headquartered in New York, the company collaborates with major healthcare firms and has received significant funding and recognition for its innovative digital therapeutics.
Services
Click Therapeutics develops and commercializes software as prescription medical treatments targeting patients with unmet medical needs. Their applications leverage cognitive and neurobehavioral mechanisms to facilitate changes within individuals. These software solutions are designed to be used independently or in combination with biomedical treatments, ensuring versatility in therapeutic approaches. The company focuses on generating real-world evidence to continuously personalize and enhance the effectiveness of their applications.
Products
Click Therapeutics offers several digital therapeutic products, including Clickotine®, designed for smoking cessation, and Rejoyn™, aimed at treating Major Depressive Disorder (MDD). The company also develops digital therapeutics for other conditions such as schizophrenia, migraine, insomnia, and acute coronary syndrome. These products are built on the Click Neurobehavioral Intervention (CNI) platform, which is supported by Clickometrics®, a data science and machine learning engine.
Collaborations
Click Therapeutics collaborates with multiple companies, such as Otsuka, Boehringer Ingelheim, Indivior, and Magellan Health, to co-develop and commercialize digital therapeutics. These partnerships aim to leverage combined expertise and resources to bring innovative digital medical treatments to market. The company engages in value-based, pay-for-performance agreements, which helps improve patient care while reducing costs.
Regulatory and Clinical Standards
Operating as a regulated Software as a Medical Device (SaMD) biotechnology company, Click Therapeutics develops its applications in compliance with FDA, ISO, and IEC standards. The company’s digital therapeutics undergo rigorous clinically controlled trials to demonstrate their safety and efficacy. By seeking FDA clearance for their apps as class II medical devices, Click Therapeutics validates independent therapeutic treatment claims or adjuncts to existing therapies. They have received FDA Breakthrough Device Designation for products addressing negative symptoms of schizophrenia and episodic migraine.
Funding and Grants
Click Therapeutics has secured significant funding to support its growth and development initiatives. The company received $30 million in growth capital from K2 HealthVentures along with $20 million in debt financing from HSBC. Additionally, Click Therapeutics was awarded a grant from the National Institutes of Health (NIH) to study digital therapeutics for smoking cessation. These financial endorsements reflect the industry's confidence in the company's innovative approach to digital therapeutics.
Company Headquarters and Locations
Click Therapeutics is headquartered in New York, NY, and maintains additional offices in Boston, MA, Miami, FL, and Raleigh, NC. This strategic geographic distribution supports their operations and expansions, enabling them to manage and collaborate efficiently across multiple regions. The company's strong physical presence in key locations underlines its commitment to advancing digital therapeutics nationwide.